Company / Operating Income
Tarsus Pharmaceuticals, Inc. Operating Income History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$71.0M
FY2025
5-year range
-$143.2M / -$12.2M
FY2021-FY2025
Trend
+41.1%
vs FY2024
Sector context
#80 of 204
Health Care
What the data says
At -$71M, Tarsus Pharmaceuticals, Inc.'s operating income ranks #80 of 204 in the Health Care sector. Improved from -$143M to -$71M over the past 2 years.
Based on SEC 10-K filings.
-$71M in FY2025.
Improved from -$143M to -$71M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#80 of 204 in Health CareTop 39% of 204This company -$71.0M Sector average $107.7M
▼
-165.9% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 41.1% year-over-year.
- Ranks #80 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2019.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$71.0M | +41.1% |
| FY2024 | -$120.6M | +15.8% |
| FY2023 | -$143.2M | -1077.6% |
| FY2022 | -$12.2M | +0.0% |
| FY2021 | -$12.2M | +55.0% |
| FY2020 | -$27.0M | -528.2% |
| FY2019 | -$4.3M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026